Syros Pharmaceuticals Inc (SYRS) FinancialsSYRSFinancialSyros Pharmaceuticals Inc

Evaluating the bottom line, Syros Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -776.96%, provide a clear picture of how effectively SYRS converts its operational activities into shareholder value.

In the context of the broader market, SYRS competes directly with industry leaders such as AWH and AQB. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SYRS's gross margin of N/A stands against AWH's 63.39% and AQB's N/A. Such benchmarking helps identify whether Syros Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.